Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
NCT06906497Phase 4Active, not recruiting
- Sponsor
- Johann E. Gudjonsson
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 4 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Johann E. Gudjonsson. Started Jul 2025; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06906497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906497.